ESTRO 2024 - Abstract Book

S1449

Clinical - Head & neck

ESTRO 2024

Recurrences occurred in 30% (n=27) patients after a median interval of 22 weeks (IQR = 6-277 weeks) following adjuvant RT. Local and distant only recurrences were 33% each, while 29% (n=25) were locoregional. Sixteen percent (n=4) failed in both loco regional and distant sites. 15.7% (n=14) of the total 89 patients were lost to follow-up. Recurrences were most common in stage IVa ,41% (n=11), followed by stage III 22% (n=6), 85% (n=23) with DOI of 4mm or higher, 16%(n=14) with lymphadenopathy, 59% (n=16) with close surgical margins and 29.6% (n=8) with tumor size >4cm. Two of the total 27 recurrences did not receive concomitant chemo and had a DOI of 4mm or more. PNI was present in 10 patients (37%) and LVI in 2 patients (7%).

Conclusion:

Our results show loco-regional recurrence is the most common failure pattern in SCC of the tongue following adjuvant chemo-radiotherapy. While factors such as tumor size, DOI, and surgical margins significantly contribute to risk of recurrences, the retrospective nature of this study causes potential biases. Nonetheless, these findings emphasize the need for tailored interventions and vigilant follow-up to improve patient outcomes.

Keywords: Recurrence, head and neck, treatment outcomes

3128

Digital Poster

Self-applied photobiomodulation therapy for radiation toxicity in head and neck cancer patients

Saeed Salman 1,2 , Ragda Abdalla-Aslan 3 , Rana Tarabeih 1 , Muhammad Awawda 1 , Salem Billan 1

1 Rambam Health Care Campus, Josef Fishman Oncology center, Haifa, Israel. 2 McGill University Health Center, Radiation Oncology Division, Montreal, Canada. 3 Rambam Health Care Campus, Oral and Maxillofacial Surgery Department, Haifa, Israel

Purpose/Objective:

Radiation-induced Oral mucositis (OM) and dermatitis (RD) are common and severe acute side effects in head and neck cancer (HNC) patients undergoing definitive radiation therapy. Photobiomodulation (PBM) applied by medical professionals is recommended by the MASCC-ISOO for OM prevention. Self-applied BPM has not been evaluated yet. The aim of this study was to evaluate the compliance and ease of use of a home PBM device in a cohort of HNC patients.

Material/Methods:

This study was a feasibility, prospective, open-label clinical trial (NCT05176834, approved by Rambam ethics committee). Patients undergoing curative radiotherapy (RT) with or without concurrent or neoadjuvant